Benaroya Research Institute
Trial Pipeline
Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms
NCT07377929
A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population
NCT06585540
Antibiotic Usage Prior to OnabotulinumtoxinA Injection
NCT04754737
Optimizing Pain Control in Transurethral Resection of the Prostate
NCT04102566
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
NCT05281614
Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy
NCT04098809
Proximal Versus Distal Adductor Canal Blocks for Total Knee Arthroplasty
NCT02701114
Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults
NCT01650870
Study on the Safety of Abatacept in Relapsing Polychondritis
NCT01272856
Preventing Propofol-associated Injection Pain
NCT00864682
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
NCT00343044
Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer
NCT00242918
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 2 |
What the Pipeline for Benaroya Research Institute Shows
According to the ClinicalTrials.gov registry, Benaroya Research Institute is linked to 12 US clinical trials across every stage of research activity. Of those, 4 studies are currently recruiting — about 33% of the sponsor's indexed portfolio — and 8 are already marked complete, representing roughly 67% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Benaroya Research Institute reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Benaroya Research Institute is Pain with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.